Organon & Co. (NYSE:OGN), a prominent player in the healthcare sector, has been garnering attention from analysts due to its diverse product portfolio and strategic market positioning. The company ...

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

Organon saw significant volatility last month with a 30% decline in its share price, coinciding with the company's announcement of decreased earnings and a reduction in its dividend payout.

JERSEY CITY, N.J. - Organon (NYSE:OGN) reported first quarter earnings that beat analyst expectations, but revenue fell short and the company’s guidance disappointed investors, sending shares ...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported first-quarter net income of $87 million. The Jersey City, New Jersey-based company said it had net ...

Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company’s webcast ...

Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of ...

Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...

Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon’s fourth quarter and full year 2024 results have not been finalized and are subject to ...